Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL966872 | 1.00 | HDAC1 (0.33) | HDAC1BACE1KDM4EMEN1ALDH1A1 | |
| SCHEMBL966907 | 0.91 | MAPT (0.36) | HDAC1SMN1; SMN2 | |
| SCHEMBL966906 | 0.91 | MAPT (0.36) | HDAC1SMN1; SMN2 | |
| SCHEMBL964972 | 0.90 | MTNR1A (0.39) | HDAC1MEN1KMT2A | |
| SCHEMBL964970 | 0.90 | MTNR1A (0.39) | HDAC1MEN1KMT2A | |
| SCHEMBL964855 | 0.89 | TLR8 (0.37) | HDAC1ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL964854 | 0.89 | TLR8 (0.37) | HDAC1ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL965978 | 0.89 | KDM4E (0.32) | HDAC1KDM4EALDH1A1GAAKMT2A | |
| SCHEMBL965035 | 0.89 | PPARG (0.36) | HDAC1 | |
| SCHEMBL965033 | 0.89 | PPARG (0.36) | HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | HDAC1 108/4885BACE1 584/4885KDM4E 1314/4885 |
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | HDAC1 338/4885BACE1 2023/4885KDM4E 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.